Non-Small-Cell LungMAPNCT07316062
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
An observational study of Non-Small-Cell Lung, run by AstraZeneca at 1 site in China.
Trial summary
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Small-Cell Lung
- How many people
- 3,000 participants
- Where
- 1 siteChina
- Study dates
- 29 Apr 2026to 30 Apr 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.
Who may be able to join
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
- For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Who cannot join
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
China1 site, 1 recruiting
- Recruiting
Research Site
Beijing
Shugeng Gao, gaoshugeng@cicams.ac.cn
About this study
Official title: A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Read the detailed description
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
- Conditions
- Non-Small-Cell Lung
- Keywords
- NSCLC, chart review
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Patterns
Proportion of patients with different treatment regimens
Measured: Up to 50 months
Proportion of unresected patients in SI/II/III
Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
Measured: Up to 50 months
CRT rate in USIII
Proportion of patients who have CRT regimen among unresected SIII patients enrolled
Measured: Up to 50 months
Secondary outcomes (3)
Treatment Duration
TKI treatment duration and discontinuation reason in EGFRm patients
- Duration of treatment
- Treatment discontinuation (time to discontinuation, and reason for discontinuation)
Measured: Up to 50 months
Patterns of recurrence
Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)
Measured: Up to 50 months
Guideline adoption rate
Resected EGFRm Stage IB-III
- Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III
- Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT
Measured: Up to 50 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start29 Apr 2026
- Primary completion30 Apr 2029 (estimated)
- Study completion30 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Small-Cell LungStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07316062
- Sponsor's protocol ID
- D133FR00236
- Acronym
- MAP
- Status last verified
- Oct 2026
- First submitted
- 5 Dec 2025
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified investigators can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
- ClinicalTrials.gov ID
- NCT07316062
- Acronym / sponsor ID
- MAP / D133FR00236
- Conditions
- Non-Small-Cell Lung
- Keywords
- NSCLC, chart review
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 29 Apr 2026 (actual)
- Primary completion
- 30 Apr 2029 (estimated)
- Study completion
- 30 Apr 2029 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Detailed description
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.
Key inclusion criteria (4 listed)
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
- For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Key exclusion criteria (4 listed)
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment Patterns
Time frame: Up to 50 months
Proportion of patients with different treatment regimens
Proportion of unresected patients in SI/II/III
Time frame: Up to 50 months
Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
CRT rate in USIII
Time frame: Up to 50 months
Proportion of patients who have CRT regimen among unresected SIII patients enrolled
3 secondary outcomes
Treatment Duration
Time frame: Up to 50 months
Patterns of recurrence
Time frame: Up to 50 months
Guideline adoption rate
Time frame: Up to 50 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: Yes. Qualified investigators can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for Non-Small-Cell Lung
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Active, not recruitingPhase 3
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
RecruitingPhase 3
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-Small-Cell Lung, run by AstraZeneca at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment Patterns (time frame: Up to 50 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.